Contemporary Approach to Desensitization: Targeted Therapies for HLA Sensitized Pediatric Heart Transplant Candidates
To study how cycles of Carfilzomib and Belatacept impact antibody composition and strength for patients who are highly sensitized.
Why this Research Matters
This multicenter study will lay the groundwork for a standardized approach to desensitization, with a goal to improve the sensitized patients' ability to be transplanted by increasing their donor pool and improve their long-term graft survival towards that of non-sensitized patients
Who can Participate
Patients between 10 and 24 years old, who are being considered for heart transplant and found to be highly sensitized Patients between 10 and 24 years old, who are being considered for HT and found to be highly sensitized with class I and or class II cPRA >/= 50% utilizing the MFI threshold of 4000 (cPRA MFI>4000 >/= 50%) will be considered for this desensitization strategy.
Study ID
Protocol Number: 24-1951
Meet the Team
Principal Investigator